The U.S. Food and Drug Administration warned Tuesday the antibiotic azithromycin, or Zithromax, may lead to a potentially fatal irregular heart beat.
The FDA said patients at particular risk for developing this condition include those with known risk factors such low blood levels of potassium or magnesium, a slower than normal heart rate, or use of certain drugs used to treat abnormal heart rhythms, or arrhythmias.
FDA issued a Drug Safety Communication as a result of its review of a study by medical researchers and another study by a manufacturer of the drug that assessed the potential for azithromycin to cause abnormal changes in the electrical activity of the heart.
Healthcare professionals should consider the risk of torsades de pointes, or rotation of the heart's electrical axis by at least 180 degrees, and fatal heart rhythms with azithromycin when considering treatment options for patients who are already at risk for cardiovascular events.
The FDA noted the potential risk of QT prolongation -- a condition whereby prolonged QT intervals are visible on the ECG -- with azithromycin should be placed in appropriate context when choosing an anti-bacterial drug.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program: www.fda.gov/MedWatch/report.htm or call 1-800-332-1088 to request a form.
Most Popular Stories
- Marketo Makes a Mint in IPO: Stock Shoots Up More than 50 Percent
- Bieber Booed at Billboard Awards
- Georgia GOP Preaches Minority Outreach
- GM Joins Nissan to Supply Small Cargo Vehicle
- Ford's Supplier Diversity Program Turns 35
- Ford Trucks See Boost as Roadshow Reaches Saudi Arabia
- Kerry Concerned Over Blasphemy Laws, Anti-Semitism
- GM to Rejoin S&P 500, Akerson Says
- Ladies in White Group Needs Help From Abroad
- NTSB Wants to Lower Blood Alcohol Limit to 0.05